

## AMENDMENTS

### Amendments to the Claims

1. (Currently amended) A cell-based method of detecting BoNT/A activity the method comprising the steps of:  
  
a) contacting a sample to a cell that contains comprising an exogenous FGFR3 and an endogenous SNAP-25, wherein said contacted cell is capable of BoNT/A intoxication and  
  
b) detecting the presence of BoNT/A activity of said contacted cell relative to a control cell, wherein a difference in the presence of endogenous SNAP-25 cleavage product from said BoNT/A activity of said contacted cell as compared to said control cell is indicative of BoNT/A activity.
2. (Withdrawal) The method according to Claim 1, wherein said cell transiently contains an exogenous FGFR3.
3. (Withdrawal) The method according to Claim 1, wherein said cell stably contains an exogenous FGFR3.
4. (Original) The method according to Claim 1, wherein said FGFR3 is a mammalian FGFR3.
5. (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a human FGFR3.
6. (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a bovine FGFR3.
7. (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a mouse FGFR3.
8. (Previously presented) The method according to Claim 4, wherein said mammalian FGFR3 is a rat FGFR3.

9. (Withdrawal) The method according to Claim 1, wherein said FGFR3 is a bird FGFR3.
10. (Withdrawal) The method according to Claim 9, wherein said bird FGFR3 is a chicken FGFR3.
11. (Withdrawal) The method according to Claim 1, wherein said FGFR3 is an amphibian FGFR3.
12. (Withdrawal) The method according to Claim 11, wherein said amphibian FGFR3 is a frog FGFR3.
13. (Withdrawal) The method according to Claim 11, wherein said amphibian FGFR3 is a newt FGFR3.
14. (Withdrawal) The method according to Claim 1, wherein said FGFR3 is a fish FGFR3.
15. (Withdrawal) The method according to Claim 15, wherein said fish FGFR3 is a zebrafish FGFR3.
16. (Original) The method according to Claim 1, wherein said cell further contains a G1b polysialoganglioside.
17. (Original) The method according to Claim 16, wherein said polysialoganglioside is selected from the group consisting of GD1a, GD1b, GD3, GQ1b, or GT1b.
18. (Original) The method according to Claim 1, wherein said cell is a neuronal cell.
19. (Original) The method according to Claim 18, wherein said neuronal cell is a primary neuronal cell.
20. (Original) The method according to Claim 18, wherein said neuronal cell is an immortalized neuronal cell.

21. (Original) The method according to Claim 18, wherein said neuronal cell is a transformed neuronal cell.
22. (Original) The method according to Claim 18, wherein said neuronal cell is selected from the group consisting of a neuroblastoma cell, a neuronal hybrid cell, a spinal cord cell, a central nervous system cell, a cerebral cortex cell, a dorsal root ganglion cell, a hippocampal cell and a pheochromocytoma cell.
23. (Withdrawal) The method according to Claim 1, wherein said cell is a non-neuronal cell.
24. (Withdrawal) The method according to Claim 23, wherein said non-neuronal cell is a primary neuronal cell.
25. (Withdrawal) The method according to Claim 23, wherein said non-neuronal cell is an immortalized neuronal cell.
26. (Withdrawal) The method according to Claim 23, wherein said non-neuronal cell is a transformed neuronal cell.
27. (Withdrawal) The method according to Claim 23, wherein said non-neuronal cell is selected from the group consisting of an anterior pituitary cell, an adrenal cell, a pancreatic cell, an ovarian cell, a kidney cell, a stomach cell, a blood cell, an epithelial cell, a fibroblast, a thyroid cell, a chondrocyte, a muscle cell, a hepatocyte, a glandular cell.
28. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a purified BoNT/A, a partially purified BoNT/A or unpurified BoNT/A.
29. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a bulk BoNT/A, a formulated BoNT/A, a cosmetics BoNT/A formulation or a clinical BoNT/A formulation.
30. (Original) The method according to Claim 1, wherein said sample is a recombinant BoNT/A.

31. (Original) The method according to Claim 1, wherein said sample is selected from the group consisting of a raw food, a cooked food, a partially cooked food or a processed food.
32. (Original) The method according to Claim 1, wherein said sample is a sample taken from a mammal.
33. (Original) The method according to Claim 32, wherein said mammalian sample is selected from the group consisting of a tissue, a saliva, an excretion or a feces.
- 34-78. (Canceled).